Welcome to Mendus’ Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.
Letter from the CEO
Well positioned to end the 2022 fiscal year on a high note
In Q3 of 2022, we brought Mendus in a strong position to reach its upcoming milestones. We have been preparing for presentation of the updated survival results from our ADVANCE II Phase 2 trial, which evaluates DCP-001 as a novel immunotherapy in AML. The data will be presented in less than a month from now at ASH, the world’s largest hematology conference. Also at ASH, we will present extensive immunomonitoring data, which have been collected as part of the ADVANCE II trial to deepen our understanding of the effect of DCP-001 on the immune system, residual disease and, most importantly, disease-free and overall survival. Positive safety data of the ALISON Phase 1 trial in ovarian cancer were presented end of October at the ESGO conference, as a first step towards this solid tumor indication. DCP-001 thus continues to be safe and well-tolerated, which is increasingly seen as a key differentiator in modern cancer medicine.
“Updated survival results from our ADVANCE II Phase 2 trial will be presented in less than a month from now at ASH, the world’s largest haematology conference.”
On the financing front, Mendus secured new financing commitments up to SEK 250M from current and new investors, allowing us to reach our near-term value inflection points on a solid financial basis and maintain operational momentum, including preparations for the scaling-up of DCP-001 manufacturing. In parallel, our in-house process development efforts are dedicated to optimizing the ilixadencel manufacturing process, as part of the preparations for next clinical development. Finally, we have made significant progress in our preclinical pipeline. We published promising data studying the combination of ilixadencel with CTLA-4 checkpoint inhibition and presented preclinical data demonstrating the synergistic combination of vaccination and intratumoral immune priming in an ovarian cancer model at ESGO. Data demonstrating the potential of the DCOne platform to selectively expand memory natural killer cells as the basis for potential novel NK cell therapies were very recently presented at the SITC conference. Our preclinical research lies the foundation for new proprietary pipeline projects and commercial opportunities in 2023 and beyond.
Based on these developments in Q3 and the beginning of Q4, Mendus is well positioned to end the 2022 fiscal year on a high note.
CEO of Mendus
*Published on Nov 11th, 2022
Keep up to date
Join our mailing list to receive our latest news.